Michael O’Rourke on Transforming Retinal Care with Long-Acting Drug Delivery

Click here to watch the video version of this podcast.

In this episode of The Rob & Jai Show, Michael O’Rourke, CEO of Re-Vana Therapeutics, joins Dr. Rob Rothman and Dr. Jai Parekh to explore the next-generation of sustained drug delivery in ophthalmology. With millions of intravitreal injections administered annually for retinal diseases like AMD, the need for longer-lasting, more effective treatments has never been greater.

O’Rourke explains how Re-Vana’s proprietary hydrogel-based technologies are setting a new standard for biodegradable, sustained-release drug implants—offering six to twelve months of therapeutic coverage without the need for surgery. The discussion covers:

How Re-Vana’s EyeLief™ and OcuLief™ technologies work to deliver biologics efficiently over extended periods.
Why reducing injection frequency is critical for patient compliance, physician workflow, and overall treatment success.
The company’s clinical and investment strategy, including a $70M Series B raise to advance its lead asset, a six-month biodegradable fluocinolone acetonide implant.
The role of strategic partnerships in accelerating innovation, as major pharma companies seek delivery solutions for their retinal therapeutics.
The global impact of sustained-release biologics, and how Re-Vana is positioning itself as a leader in both the U.S. and European markets.

With a team of seasoned industry experts, strong investor backing, and an unwavering commitment to innovation, Re-Vana Therapeutics is redefining how we approach retinal disease treatment.

Don’t miss this insightful conversation—subscribe to the OIS podcast today and stay ahead of the curve in ophthalmic innovation!

Resources:
Dr. Robert Rothman: https://ois.net/robert-rothman-md/
Dr. Jai Parekh: https://ois.net/jai-g-parekh-md-mba/
Michael J. O’Rouke: https://ois.net/michael-orourke//